ArticleTherapeutic advances in chronic disease2020
Prediction of therapeutic efficacy of gabapentin by Hull Airway Reflux Questionnaire in chronic refractory cough.
Article in Therapeutic advances in chronic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.BMC medicine · 2026Trial
- Article
- Real-world usage and response to gefapixant in refractory chronic cough.ERJ open research · 2025Article
- The development of the Cough Hypersensitivity Questionnaire for chronic cough.ERJ open research · 2024Article
- Patient-reported assessments of chronic cough in clinical trials: accessory or primary endpoints?Journal of thoracic disease · 2024Review
- Qualitative assessment of sensations and triggers in chronic cough.ERJ open research · 2024Article
- New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study.Allergy, asthma & immunology research · 2023Article
- Pathogenesis and management of gastroesophageal reflux disease-associated cough: a narrative review.Journal of thoracic disease · 2023Review
- Chronic cough-the limitation and advances in assessment techniques.Journal of thoracic disease · 2022Review
- Chronic cough: new insights and future prospects.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Predicting response to neuromodulators in refractory chronic cough: An interpretable machine learning approach.Therapeutic advances in respiratory diseaseObservational
- Predictive Factors and Treatment Effects of Neuromodulators in Chronic Refractory Cough.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeArticle
- Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.Therapeutic advances in respiratory diseaseObservational
- Evaluation methods and influencing factors of cough sensitivity.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGabapentin is recommended for the treatment of chronic refractory cough (CRC). This study aims to identify its therapeutic predictors in a prospective clinical study.
methodsA total of 179 patients with CRC were treated with gabapentin. Prior to the therapy, all patients were assessed by Hull Airway Reflux Questionnaire (HARQ) and inhaled capsaicin challenge. When the treatment ended and cough resolution was confirmed, a stepwise logistic regression analysis was performed to identify the therapeutic predictors for gabapentin and to establish the prediction equation.
resultsGabapentin treatment achieved a therapeutic success rate of 66.48%. HARQ scores were significantly higher in responders than non-responders to gabapentin (29.79 ± 9.58
conclusionHARQ may be useful to screen patients with CRC most likely responsive to gabapentin, and help improve the therapeutic success.
trial registrationhttp://www.chictr.org/; No.: ChiCTR-ONC-13003123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.